Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Refractory Seizures Clear all
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739
View directory record Official record
Conditions
Super-refractory Status Epilepticus
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Birmingham, Alabama • Sarasota, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 23, 2026, 8:17 PM EDT
Enrolling by invitation Not applicable Interventional

Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy

NCT07353918
View directory record Official record
Conditions
Epilepsy (Treatment Refractory), Epilepsy Comorbidities
Interventions
Low-intensity Focused Ultrasound, Sham
Device
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 23, 2026, 8:17 PM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy

NCT04219995
View directory record Official record
Conditions
Intractable Epilepsy, Convulsive Seizures
Interventions
methylprednisolone sodium succinate, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 23, 2026, 8:17 PM EDT
Terminated Phase 4 Interventional Results available

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

NCT04650204
View directory record Official record
Conditions
Intractable Epilepsy, Malignant Glioma, Seizure Disorder, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Anticonvulsant Agent, Perampanel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 8:17 PM EDT
Recruiting Not applicable Interventional

Non-Invasive Low Intensity Focused Ultrasound Stimulation for Drug-Resistant Epilepsy

NCT07680842
View directory record Official record
Conditions
Drug-Resistant Epilepsy, Epilepsy, Epilepsy (Treatment Refractory), Epilepsy Comorbidities, Epilepsy, Drug Resistant, Epilepsy, Generalized, Epilepsy, Focal
Interventions
Target optimization using LIFU, Serial LIFU stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699582
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
32
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 23, 2026, 8:17 PM EDT
Withdrawn Phase 3 Interventional

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

NCT04558580
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
Rufinamide
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
12 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00735397
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years and older
Enrollment
1,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

NCT00175825
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Not applicable Interventional

Modified Atkins Diet Plus KetoCal for Adult Epilepsy

NCT01834482
View directory record Official record
Conditions
Epilepsy, Seizure, Medically Resistant Epilepsy, Medically Resistant Seizures
Interventions
Modified Atkins diet, KetoCal
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 23, 2026, 8:17 PM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 8:17 PM EDT
Recruiting Not applicable Interventional

Sleep-Sensitive Seizure Risk Assessment With Wearable EEGs

NCT06545643
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Dreem headband
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 23, 2026, 8:17 PM EDT
Active, not recruiting Phase 2 Interventional

RNS System LGS Feasibility Study

NCT05339126
View directory record Official record
Conditions
Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures, Seizures, Generalized
Interventions
RNS System
Device
Lead sponsor
NeuroPace
Industry
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

4-Year Open-Label Extension Phase of the Parallel-Group Study of E2007 in Patients With Refractory Partial Seizures

NCT00368472
View directory record Official record
Conditions
Epilepsy
Interventions
Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 2 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732
View directory record Official record
Conditions
PCDH19-Related Epilepsy
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2023 · Synced Sep 23, 2026, 8:17 PM EDT
Completed No phase listed Observational

Vagus Nerve Stimulation Clinical Outcomes Measured Prospectively in Patients Stimulated

NCT01281293
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
Cyberonics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
7
States / cities
Atlanta, Georgia • Peoria, Illinois • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 23, 2026, 8:17 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

NCT04015141
View directory record Official record
Conditions
Pediatric Epileptic Syndrome, Partial-onset Seizures
Interventions
Perampanel Oral Suspension, Perampanel Tablet
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Los Angeles, California • Aurora, Colorado • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 3 Interventional

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

NCT00175890
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 4 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2020 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

NCT00988429
View directory record Official record
Conditions
Partial Epilepsy
Interventions
800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
16 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
106
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 23, 2026, 8:17 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Refractory Status Epilepticus

NCT00265616
View directory record Official record
Conditions
Status Epilepticus
Interventions
propofol, thiopental/pentobarbital
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 23, 2026, 8:17 PM EDT
Terminated Phase 3 Interventional Results available

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539
View directory record Official record
Conditions
Refractory Partial Onset Seizures
Interventions
Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Little Rock, Arkansas • Bradenton, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 23, 2026, 8:17 PM EDT
Completed Phase 3 Interventional Results available

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

NCT00334958
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
77
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 23, 2026, 8:17 PM EDT
Recruiting Not applicable Interventional

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

NCT07012148
View directory record Official record
Conditions
Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
Interventions
UNEEG SubQ device
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 23, 2026, 8:17 PM EDT